Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Science
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Find Cricket Statistics
Hindi
More
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Science
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Find Cricket Statistics

More Links
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / India News / COVAXIN is 200% safe: Bharat Biotech MD on efficacy concerns
  • India

    COVAXIN is 200% safe: Bharat Biotech MD on efficacy concerns

    Siddhant Pandey
    Written by
    Siddhant Pandey
    Twitter
    Last updated on Jan 04, 2021, 10:54 pm
    COVAXIN is 200% safe: Bharat Biotech MD on efficacy concerns
  • Bharat Biotech MS Krishna Ella on Monday said the company has "tremendous experience" in developing vaccines and their vaccine, COVAXIN, is "200% safe."

    The statement comes amid backlash over emergency approval for the restricted use of the vaccine, which was granted on Sunday.

    Some experts and the Opposition have questioned the regulatory approval in the absence of efficacy data from Phase III trials.

  • In this article
    COVAXIN Phase III trials still underway 'Merck's Ebola vaccine received emergency approval without trial' 'Not a company without experience; we don't deserve this' 'People should have patience to read our articles' COVAXIN showed less than 10% adverse reactions, says Ella COVAXIN will work better against new strain, says government
  • Vaccine

    COVAXIN Phase III trials still underway

    COVAXIN Phase III trials still underway
  • COVAXIN is an inactivated vaccine, i.e., it uses an inactivated or killed pathogen (SARS-CoV-2) to trigger an immune response.

    It has been developed jointly by Bharat Biotech and the Indian Council of Medical Research's National Institute of Virology (ICMR-NIV).

    Phase III trials of the vaccine are yet to be completed, however, at least 22,500 out of 25,800 intended subjects have been vaccinated.

  • Quote

    'Merck's Ebola vaccine received emergency approval without trial'

  • Addressing a presser, Ella said, "Merck's Ebola vaccine never completed a human clinical trial at all but WHO gave emergency authorization for Liberia and Guinea."

    He said, "Now that the vaccine is being politicized, I want to state very clearly that none of my family members is associated with any political party. Many people are just gossiping. It's just a backlash against Indian companies."

  • Experience

    'Not a company without experience; we don't deserve this'

    'Not a company without experience; we don't deserve this'
  • Ella said the company does not deserve the backlash as they have submitted sufficient data that is available on the internet.

    "We are not a company without experience in vaccines," he said, "We are touching 123 countries. We are the only company that has got such extensive experience and extensive publication in review journals."

    COVAXIN trials were conducted in over 12 countries, he added.

  • Quote

    'People should have patience to read our articles'

  • Ella further said, "Many people say that I am not transparent in my data. I think people should have the patience to read on the internet and how many articles we have published. More than 70 articles have been published in various international journals."

  • Safety

    COVAXIN showed less than 10% adverse reactions, says Ella

  • Ella said, "COVAXIN has shown less than 10% adverse reactions, while others have 60-70% adverse reactions. AstraZeneca was giving 4g paracetamol to volunteers to suppress such reactions. We haven't given paracetamol to any volunteer."

    "I can assure you our vaccine is 200% safe," he said.

    Ella also requested a week's time for confirmed data on the vaccine's efficacy against the new strain of coronavirus.

  • New strain

    COVAXIN will work better against new strain, says government

    COVAXIN will work better against new strain, says government
  • A new strain of SARS-CoV-2 has caused a stir as authorities say it can be as much as "70% more infectious."

    India has reported at least 52 such cases so far.

    Health Minister Dr. Harsh Vardhan and ICMR Director-General Dr. Balram Bhargava have said that COVAXIN has a better chance against the new strain as it uses a killed version of the whole virus.

  • Health Ministry
  • Harsh Vardhan
  • Coronavirus
  • Balram Bhargava
  • Bharat Biotech
  •  
Latest News
  • Ellie Goulding expecting first child, is almost 8 months pregnant
    Ellie Goulding expecting first child, is almost 8 months pregnant
    Entertainment
  • New coronavirus variants in India: All you need to know
    New coronavirus variants in India: All you need to know
    Science
  • Yogi Adityanath takes jibe at Samajwadi Party's red cap
    Yogi Adityanath takes jibe at Samajwadi Party's red cap
    Politics
  • India vs England: Visitors manage only 112 in first innings
    India vs England: Visitors manage only 112 in first innings
    Sports
  • Undertrial killed inside Tihar, HC expresses shock: Details
    Undertrial killed inside Tihar, HC expresses shock: Details
    Delhi
Related Timelines
  • SII, Bharat Biotech ensure 'smooth roll out' of vaccines globally
    SII, Bharat Biotech ensure 'smooth roll out' of vaccines globally
    India
  • All you need to know about vaccines approved in India
    All you need to know about vaccines approved in India
    India
  • SII's Covishield, Bharat Biotech's COVAXIN granted emergency approval, says DCGI
    SII's Covishield, Bharat Biotech's COVAXIN granted emergency approval, says DCGI
    India
  • Coronavirus vaccine: Bharat Biotech's COVAXIN gets expert panel nod
    Coronavirus vaccine: Bharat Biotech's COVAXIN gets expert panel nod
    India
Trending Topics
ISRO Vaccine Farmers Protest Uttarakhand Glacier Disaster Toolkit Case
Next News Article
Share
Cancel

Want to share it with your friends too?

Facebook Whatsapp Twitter Linkedin
Copied

Love India news?

Subscribe to stay updated.

India Thumbnail
India News Business News World News Politics News Sports News Science News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Bharti Airtel Mukesh Ambani Indian Premier League Samsung Virat Kohli Rohit Sharma
Cricket News Facebook YouTube Hollywood News WhatsApp Netflix Bollywood News ISRO Spotify Yoga
Honda Batman Football News BMW Vaccine Reliance Jio OPPO Food News, Healthy Recipes Royal Challengers Bangalore Toyota
Fashion Tips Ishant Sharma Farmers Protest Mercedes Isha Ambani India Vs England Cricket OnePlus Mobiles Android TV Smart TV Robert Lewandowski
Marvel Comics Avengers Neha Kakkar Mena Massoud
About Us Privacy Policy Terms & Conditions Contact Us News News Archive Topics Archive Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2021